The Experts below are selected from a list of 294 Experts worldwide ranked by ideXlab platform
Theodoros Stefos - One of the best experts on this subject based on the ideXlab platform.
-
Clinical practice guidelines on Diabetes Mellitus and pregnancy: ΙI. Gestational Diabetes Mellitus
Hormones, 2020Co-Authors: Eleni Anastasiou, Georgios Farmakidis, Angeliki Gerede, Dimitrios G. Goulis, Eftychia Koukkou, Anargyros Kourtis, Apostolos Mamopoulos, Kassiani Papadimitriou, Vasilios Papadopoulos, Theodoros StefosAbstract:Gestational Diabetes Mellitus (GDM) is the most common metabolic disease of pregnancy and is associated with several perinatal complications. GDM is defined as Diabetes diagnosed in the second or third trimester of pregnancy that was not clearly overt Diabetes prior to gestation. In Europe, in 2016, the prevalence of GDM was estimated to be 5.4% (3.8–7.8). It varied depending on maternal age, year of data collection, country, area of Europe, week of gestation at testing, and diagnostic criteria. The Hellenic Endocrine Society and the Hellenic Society of Maternal-Fetal Medicine commissioned an expert group to construct national guidelines on “Diabetes Mellitus and pregnancy: Gestational Diabetes Mellitus.” Following a search for the best available evidence and critical appraisal of the results, the writing group generated a series of consensus recommendations regarding screening tests for the general population, monitoring and management, fetal monitoring, management of preterm labor, planning of labor and delivery, puerperium and breastfeeding, and long-term follow-up of GDM.
R.-m. Szeimies - One of the best experts on this subject based on the ideXlab platform.
-
Hautveränderungen bei Diabetes Mellitus
Der Hautarzt, 2004Co-Authors: M. Meurer, M. Stumvoll, R.-m. SzeimiesAbstract:Diabetes Mellitus is the most frequent metabolic disorder. Just under 5 million people suffer from this disease in Germany. Four types of Diabetes Mellitus are distinguished: type 1 Diabetes, type 2 Diabetes, other specific Diabetes forms, and gestational Diabetes. Many characteristics of Diabetes Mellitus including skin changes are already manifest in the “prediabetic” stage when glucose tolerance is limited so that every elevation of blood sugar levels must be considered pathological. Changes in skin due to Diabetes Mellitus can be categorized into four disease groups: skin infections, skin diseases found overly frequently in association with Diabetes Mellitus, skin alterations due to diabetic complications, and reactions to antidiabetic treatment. Diabetes Mellitus ist die häufigste Stoffwechselerkrankung. In Deutschland leiden knapp 5 Mio. Menschen daran. Es werden 4 Typen von Diabetes Mellitus unterschieden: Typ-1-Diabetes, Typ-2-Diabetes, andere spezifische Diabetesformen und GestationsDiabetes. Viele Merkmale des Diabetes Mellitus, darunter auch Hautveränderungen, finden sich bereits im „vordiabetischen“ Stadium der eingeschränkten Glukosetoleranz, sodass jede Erhöhung des Blutzuckers als pathologisch betrachtet werden muss. Die Hautveränderungen bei Diabetes Mellitus können 4 Krankheitsgruppen zugeordnet werden: Hautinfektionen, Hauterkrankungen mit überhäufiger Assoziation zu Diabetes Mellitus, durch diabetische Komplikationen bedingte Hautveränderungen und Reaktionen auf die antidiabetische Therapie.
-
Hautveränderungen bei Diabetes Mellitus
Hautarzt, 2004Co-Authors: M. Meurer, M. Stumvoll, R.-m. SzeimiesAbstract:Diabetes Mellitus ist die haufigste Stoffwechselerkrankung. In Deutschland leiden knapp 5 Mio. Menschen daran. Es werden 4 Typen von Diabetes Mellitus unterschieden: Typ-1-Diabetes, Typ-2-Diabetes, andere spezifische Diabetesformen und GestationsDiabetes. Viele Merkmale des Diabetes Mellitus, darunter auch Hautveranderungen, finden sich bereits im „vordiabetischen“ Stadium der eingeschrankten Glukosetoleranz, sodass jede Erhohung des Blutzuckers als pathologisch betrachtet werden muss. Die Hautveranderungen bei Diabetes Mellitus konnen 4 Krankheitsgruppen zugeordnet werden: Hautinfektionen, Hauterkrankungen mit uberhaufiger Assoziation zu Diabetes Mellitus, durch diabetische Komplikationen bedingte Hautveranderungen und Reaktionen auf die antidiabetische Therapie.
Yashpal Gogate - One of the best experts on this subject based on the ideXlab platform.
-
Type 1 Diabetes Mellitus
Clinical Rounds in Endocrinology, 2020Co-Authors: Anil Bhansali, Yashpal GogateAbstract:Why was nomenclature changed from insulin-dependent Diabetes Mellitus to type 1 Diabetes Mellitus?
Martin L. Milgrom - One of the best experts on this subject based on the ideXlab platform.
-
Post-Transplant Diabetes Mellitus
Drug Safety, 1997Co-Authors: Rahul M. Jindal, Richard A. Sidner, Martin L. MilgromAbstract:Immunosuppressive agents increase the risk of death due to coronary disease or stroke by their ability to cause 3 different adverse effects: dyslipidaemia, hypertension and hyperglycaemia. Post-transplant Diabetes Mellitus has emerged as a major adverse effect of immunosuppressants. As recipients of organ transplants survive longer, the secondary complications of Diabetes Mellitus have assumed greater importance. There is a need for a precise definition of post-transplant Diabetes Mellitus to facilitate inter-centre comparison and to study the natural history of post-transplant Diabetes Mellitus. We recommend broad criteria to define hyperglycaemia, as a fasting blood glucose level of >400 mg/dl at any point or >200 mg/dl for 2 weeks, or a need for insulin treatment for at least 2 weeks. We also recommend serial measurements of HbA_1c. Cyclosporin and tacrolimus cause post-transplant Diabetes Mellitus by a number of mechanisms, including decreased insulin secretion, increased insulin resistance or a direct toxic effect on the beta cell. For corticosteroids, the induction of insulin resistance seems to be the predominant factor. However, few studies have examined the mechanism of diabetogenicity at the molecular level. This may hold the key for pharmacological manipulation of current immunosuppressive regimens which may result in decreased metabolic complications. Corticosteroid sparing regimens have been shown to reduce the metabolic complications of immunosuppressants including post-transplant Diabetes Mellitus. However, their use should be balanced against the increased incidence of transplant rejections. Post-transplant Diabetes Mellitus may be organ-specific, irrespective of the immunosuppressant used. Tacrolimus causes a high incidence of post-transplant Diabetes Mellitus in recipients of kidney transplants (up to 20% in some reports); the diabetogenicity of cyclosporin-based regimens is comparable with that of tacrolimus-based regimens in recipients of liver transplants. A few clinical studies in which attempts were made to discontinue cyclosporin resulted in an unacceptable loss of the transplant. In the case of tacrolimus, complete withdrawal of immunosuppression may be possible in selected patients with liver transplants. However, post-transplant recipients who may benefit from this approach are difficult to identify. In some early series, patients received doses of tacrolimus that were approximately 2 to 3 times higher than those currently used, which may have resulted in a higher incidence of post-transplant Diabetes Mellitus. More recently, it has been shown that tacrolimus was successful in salvaging whole pancreatic grafts which were maintained on cyclosporin. Tacrolimus-based immunosuppression as primary therapy was also used with remarkable success in solitary whole pancreas transplants. Strategies to reduce the metabolic complications of immunosuppressants should be pursued aggressively as this will directly lead to a decrease in long term cardiovascular adverse effects.
Eleni Anastasiou - One of the best experts on this subject based on the ideXlab platform.
-
Clinical practice guidelines on Diabetes Mellitus and pregnancy: ΙI. Gestational Diabetes Mellitus
Hormones, 2020Co-Authors: Eleni Anastasiou, Georgios Farmakidis, Angeliki Gerede, Dimitrios G. Goulis, Eftychia Koukkou, Anargyros Kourtis, Apostolos Mamopoulos, Kassiani Papadimitriou, Vasilios Papadopoulos, Theodoros StefosAbstract:Gestational Diabetes Mellitus (GDM) is the most common metabolic disease of pregnancy and is associated with several perinatal complications. GDM is defined as Diabetes diagnosed in the second or third trimester of pregnancy that was not clearly overt Diabetes prior to gestation. In Europe, in 2016, the prevalence of GDM was estimated to be 5.4% (3.8–7.8). It varied depending on maternal age, year of data collection, country, area of Europe, week of gestation at testing, and diagnostic criteria. The Hellenic Endocrine Society and the Hellenic Society of Maternal-Fetal Medicine commissioned an expert group to construct national guidelines on “Diabetes Mellitus and pregnancy: Gestational Diabetes Mellitus.” Following a search for the best available evidence and critical appraisal of the results, the writing group generated a series of consensus recommendations regarding screening tests for the general population, monitoring and management, fetal monitoring, management of preterm labor, planning of labor and delivery, puerperium and breastfeeding, and long-term follow-up of GDM.